Glial Progenitor Cell Aggregates Without Xenogeneic Feeder Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing cell aggregates containing glial progenitor cells often include xenogeneic-cell-derived components, which are unsuitable for clinical applications, and lack clarity on the optimal cell types and quantities for therapeutic efficacy in treating spinal cord injuries.
Innovation Solution
A method is developed to produce cell aggregates comprising glial progenitor cells without xenogeneic-cell-derived components, using a serum-free suspension culture and specific culture media with SMAD and Wnt signaling modulators, enabling stable formation of cell aggregates with high differentiation potential into oligodendrocytes, astrocytes, and neural cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If feeder cells are used in the culture method, then cell aggregate formation is supported, but xenogeneic-cell-derived components are introduced which are unsuitable for clinical applications
Solution Approach 1:
The invention extracts and removes the harmful element (feeder cells containing xenogeneic components) from the culture system while maintaining the essential function of supporting cell aggregate formation through alternative means (chemically defined medium with specific growth factors and signaling modulators)
Solution Approach 2:
The invention introduces intermediary substances (chemically defined growth factors, SMAD signaling inhibitors, Wnt signaling activators) that mediate the cell culture process without requiring feeder cells, thereby eliminating xenogeneic contamination while maintaining culture support functions
2Productivity
If conventional differentiation methods are used, then neural progenitor cells can be induced, but the optimal cell types and quantities for therapeutic efficacy remain unclear
Solution Approach 1:
The invention systematically changes culture parameters (adding specific growth factors, modulating signaling pathways through SMAD inhibitors and Wnt activators, optimizing culture duration) to achieve optimal differentiation outcomes and identify therapeutic efficacy parameters
3Productivity
If cell aggregates are produced for clinical use, then large quantities are needed, but contamination with infectious factors must be avoided
Solution Approach 1:
The invention applies localized quality control by using chemically defined, xeno-free culture components throughout the production process, ensuring that each stage of cell aggregate production maintains infection-free status while scaling up quantity
Data Source
AI summary
The method for producing a cell aggregate including glial progenitor cells according to the present invention comprises:(1) a step of subjecting pluripotent stem cells to suspension culture in an embryoid-body-forming culture medium containing one or more SMAD signaling inhibitors and one or more Wnt signaling activators in the absence of feeder cells for 5 days to 10 days, to form a cell aggregate;(2) a step of subjecting the cell aggregate obtained in (1) to suspension culture in an embryoid-body-forming culture medium containing retinoic acid;(3) a step of subjecting the cell aggregate obtained in (2) to suspension culture in an embryoid-body-forming culture medium or neuron-and-glia-proliferating culture medium containing retinoic acid and one or more SHH signaling activators; and(4) a step of subjecting the cell aggregate obtained in (3) to suspension culture in a neuron-and-glia-proliferating culture medium containing no retinoic acid and one or more SHH signaling activators.